Form 4: Tourmaline Bio Executive Granted Stock Options

Kevin Bruce Johnson, Chief Regulatory Officer of Tourmaline Bio, Inc., was granted stock options for 58,000 shares on January 27, 2025.

Summary

• Kevin Bruce Johnson, Chief Regulatory Officer of Tourmaline Bio, Inc., filed a Form 4.
• On January 27, 2025, Johnson was granted employee stock options for 58,000 shares of Tourmaline Bio common stock at an exercise price of $17.
• The options vest as to 25% of the shares on January 27, 2026, with the remaining shares vesting in 36 equal monthly installments, contingent upon continued service.
• The options expire on January 26, 2035.
• Following the transaction, Johnson directly owns 58,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine corporate action that aligns management with shareholders.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and company growth.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value and incentivizing long-term performance. This grant is typical for a Chief Regulatory Officer in a company like Tourmaline Bio.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in the biotechnology industry.
• The size of the grant (58,000 shares) and the vesting schedule (25% after one year, then monthly) appear to be within typical ranges for a company of Tourmaline Bio's size and stage.
• Comparable companies often use similar vesting schedules to retain key personnel and incentivize long-term performance.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Regulatory Officer to contribute to the company's success.
• The employee benefits from the potential future value of the stock options.

Key Dates